News and Trends 13 Dec 2022
Therabest and Glycotope to assess breast cancer combination treatment
Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNK (enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s…
